Gilead Invests In Synthetic Biology Partnership For Next Gen CAR-Ts

Adapted Cells Can Sense Tumor Microenvironment

 
• By Andrew McConaghie

Gilead’s Kite is the current leader in CAR-T, but is looking for ways to stay ahead of competitors and find safer and more effective next-generation therapies.

Gilead_USA
Gilead's Yescarta is set to exceed sales of $1bn for the first time this year, but could face 'off the shelf' competition soon. • Source: Gilead

More from Business

More from Scrip